ProMIS Neurosciences (PMN)
Develops EpiSelect-discovered antibodies for protein-misfolding neurodegenerative disorders.
Something off on this page? Send us feedback.
Develops EpiSelect-discovered antibody candidates for Alzheimer's and other neurodegenerative disorders driven by misfolded proteins. With no approved products or revenue, it is a single-segment R&D business whose only clinical-stage candidate is PMN310.
Develops antibodies against disease-specific epitopes exposed on toxic, misfolded proteins through EpiSelect, its computational discovery platform. PMN310, the only clinical-stage candidate, is designed for Alzheimer's disease to bind toxic amyloid-beta oligomers while avoiding monomer, plaque, and vascular deposits.
Advances PMN267 for TDP-43 disorders and PMN442 for alpha-synuclein disorders in preclinical development, alongside the PMN311 and PMN440 vaccine programs. Toronto serves as the registered head office, with an office in Cambridge, Massachusetts, U.S. clinical sites, and Canadian research relationships.
Operates as a small R&D organization with no approved products or product revenue. Manufacturing is intended to be outsourced where practical, and future commercialization is expected to rely on partners; progress is concentrated on PMN310's clinical and regulatory development.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 21, 2026 | Roth Capital | Target | Target: $19 | Target: $29 |
| Jul 28, 2026 | Chardan Capital | Reiterate | Rating: —Target: $20 | Target: $33 |
| Jul 27, 2026 | Chardan Capital | Target | Target: — | Target: $20 |
| Jul 7, 2026 | Roth Capital | Initiate | Rating: —Target: — | Target: $19 |
| Jun 30, 2026 | Cantor Fitzgerald | Initiate | Rating: — |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $53.5M · Total debt $0 · Total assets $56.7M · Shareholders' equity $49.4M
- Revenue
- $0
- Operating income
- −$12.3M
- Net income
- −$11.7M
No dividends on record.
| Institutions | 71.39% | 6.40M shares | |
|---|---|---|---|
| 27 holders · as of Jun 30, 2026 | |||
| Insiders | 14.40% | 1.29M shares | |
| 10 holders · as of Aug 7, 2026 | |||
| Strategic holders | 39.42% | 3.53M shares | |
| 5 holders · as of Apr 7, 2026 | |||
| Adds to | 125.21% | ||
8.97M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (8.97M in the company's Sep 23, 2026 report, 1.31M elsewhere); stakes use the report.
These groups come from separate filings that can overlap, so they add to 125.21%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Janus Henderson Group PLCStrategic | 14.42% | 1.29M | filed Apr 7, 2026 |
Jupiter Topco LLCInstitution | 14.42% | 1.29M | as of Jun 30, 2026 |
ABG Management Ltd.Strategic10 percent owner | 10.52% | 943,090 | filed Feb 5, 2026 |
ABG V-SIV IX LtdStrategic10 percent owner | 10.52% | 943,090 | filed Feb 25, 2026 |
Wellington Biomedical Innovation Master Investors (Cayman) II, L.P.Insider | 9.99% | 895,877 | filed Mar 18, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 5, 2026 | Johanne Kaplan | officer: Chief Development Officer | +2,280 | $13.30 |
| Apr 22, 2026 | Patrick D. Kirwin | director | +4,000 | $11.33 |
| Mar 5, 2026 | Eugene Williams | director | +2,000 | $24.40 |
| Mar 2, 2026 | Eugene Williams | director | +1,000 | $22.53 |
| Mar 3, 2026 | Eugene Williams | director | +1,000 | $21.89 |
- Eli Lilly
Approved anti-amyloid leader in early Alzheimer's disease.
- Biogen
Leqembi co-developer with an approved early-AD antibody.
- Acumen Pharmaceuticals
Closest clinical rival in soluble amyloid-beta oligomer antibodies.
- AC Immune
Active anti-amyloid vaccine program for early Alzheimer's disease.
- Cognition Therapeutics
Oligomer-toxicity program pursuing the same Alzheimer's patients.
- Annovis Bio
Dual Alzheimer's and Parkinson's program with protein-target breadth.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| ProMIS Neurosciences | $13.34 | −1.80% | $17.8M | — | — | — | — |
| Eli Lilly | $1,154.59 | −1.33% | $1.10T | 39.3 | 28.2 | 13.8 | +47.7% |
| Biogen | $223.76 | −0.71% | $33.30B | 39.9 | 16.9 | 3.3 | +3.4% |
| Acumen Pharmaceuticals | $2.42 | −8.87% | $191.4M | — | — | — | — |
| AC Immune | $2.77 | +1.46% | $277.8M | — | — | 13.1 | +823.6% |
| Cognition Therapeutics | $0.9700 | −1.15% | $87.8M | — | — | — | — |
| Annovis Bio | $1.29 | +2.02% | $53.6M | — | — | — | — |
| Median | 39.6 | 22.6 | 13.1 | +47.7% |